Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

October 25, 2005 09:10 ET

Swiss Medica Announces Major, Nationwide Media Campaign To Support Media Launch Of O24 Fibromyalgia

TORONTO, ONTARIO--(CCNMatthews - Oct. 25, 2005) -

Studio City, California based TVA Productions will produce intensive media campaign to build awareness of recently-announced, increasingly popular fibromyalgia pain relief solution

Swiss Medica, Inc. (OTCBB:SWME) today announced that it has engaged TVA Productions of Studio City, California to create and execute a major media campaign for the company as a key element in the media launch of O24 Fibromyalgia.

"The National Fibromyalgia Association (NFA) estimates that up to 11 million people throughout the United States are suffering from the pain of living with fibromyalgia - we want to ensure that every one of them is aware that we offer a patented and clinically tested, strong and safe, all-natural, over-the-counter health product developed to specifically address the symptoms of long term pain associated with fibromyalgia," said Swiss Medica President & COO Grant Johnson "This campaign builds on the strategic partnership we announced in June with the National Fibromyalgia Association. As part of that partnership, Swiss Medica O24 Fibromyalgia became the first product to be granted the NFA's Seal of Approval. No-one suffering from the pain associated with fibromyalgia should suffer another day of pain because they were unaware of the relief that can be provided by O24 Fibromyalgia."

The "MediaBlitz" campaign to be conducted by TVA Productions is based on guaranteed results and will include:

- 41,000,000 estimated gross viewer impressions.

- Segments featured on 1/2 hour TV newsmagazines airing nationwide.

- Broadcast-quality 90 second video News Release followed by up to 13 minutes of B-Roll and Sound Bites, distributed via satellite and Beta to more than 1,100 TV stations across the country.

- Broadcast Masters for inclusion on national and local news programs and talk shows.

- 1-3 column news article with photo and contact info distributed to over 10,000 newspapers reaching an estimated audience of more than 20,000,000 readers.

- A 60 second Radio News release professionally recorded and distributed in script form and on CD to 6,600 radio stations for use on regular news and talk shows.

- Several production guarantees and media placement guarantees, with distribution to the major news networks based in the US.

- At least 30 days of in-flight entertainment on one major airline in the US.

"I have every expectation that our campaign for Swiss Medica will be one of our most successful to date," said TVA Productions President Jeffery Goddard. "The successful launch of Swiss Medica's O24 Fibromyalgia pain relief solution is a story that has all the right 'ingredients' for us to create compelling, newsworthy news features that are sure to generate a massive amount of positive exposure among the 20,000-plus media outlets which receive our news feeds."

About TVA

TVA is a North American media production and news placement syndicate based in Studio City, California. It offers HD (High Definition) production facilities, extensive distribution & tracking resources, and a worldwide team of media experts. The company specializes in not only producing promotional media and News Features for TV, Radio Print and the Internet-but using its extensive distribution arrangements with more than 20,000 media outlets, TVA is able to guarantee thousands of placements on national and local television and radio stations, in newspapers, and in in-flight programming on major airlines.

About Swiss Medica, Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com ,www.O24zone.com and www.pmsescape.com.

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica is launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can visit www.024zone.com for information on O24 Fibromyalgia and to order the product online.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and purchases and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Swiss Medica, Inc.
    Investor Relations Contact:
    David Jones
    (866) 485-4243
    or
    Fusion Communications
    Public Relations Contact:
    Dean Mailey
    (604) 218-6767
    dean@fusioncom.ca
    or
    Stern & Co.
    Financial Media Contact: Stan Froelich
    VP, Media Relations
    (212) 888-0044
    sfroelich@sternco.com